Breaking News

Affimed, Roche Explore AFM24, Tecentriq Combo

To investigate the combination for the treatment of advanced solid epidermal growth factor receptor (EGFR) expressing malignancies.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Affimed N.V., a clinical-stage immuno-oncology company, entered a clinical research collaboration with Roche to explore the combination of Affimed’s innate cell engager (ICE) AFM24 with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq).   Affimed will fund and conduct a Phase 1/2a trial to investigate the combination of AFM24 and atezolizumab for the treatment of advanced solid epidermal growth factor receptor (EGFR) expressing malignancies in patients whose disease has progressed af...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters